https://bi1744agonist.com/eval....uation-of-the-partic
We enrolled 97 patients with FH WTs (median follow-up, 71.5 months; range, 22.2-170.7). The full total recurrence rate ended up being 17.5%, as well as the subtype recurrence prices had been as follows blastemal predominant (45.5%), blended (7.5%), epithelial (14.3%), and mesenchymal (9.5%) (P=.01. Five-year event-free success (EFS) and total survival (OS) prices were 84.9% and 81.4%, correspondingly. Respective 5-year EFS and OS rates for sual confoundi
Like
Comment
Share
